Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
By developing new pyrazolo[1,5-a]pyrimidine compounds as CDK inhibitors, the limitations of existing CDK inhibitors in the treatment of CDK-related diseases have been solved, effective inhibition of CDK2 and CDK4 has been achieved, and provided New treatments to address the challenges of cancer and other proliferative diseases.
Patent Information
- Application Number
- CN03824701.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2002-09-04
- Filing Date
- 2003-09-03
- Publication Date
- 2005-11-23
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing cyclin-dependent kinase (CDK) inhibitors have limitations in the treatment of cancer and other proliferative diseases. In particular, they are not effective enough in regulating CDK2 and CDK4, resulting in limited therapeutic effects.
A new class of pyrazolo[1,5-a]pyrimidine compounds were developed as CDK inhibitors. Through specific structural design and synthesis routes, compounds with potential therapeutic effects were prepared and applied to pharmaceutical compositions and in treatment.
These compounds display significant CDK inhibitory activity and can effectively inhibit the progression of cancer and other proliferative diseases, providing new possibilities for the treatment of CDK-related diseases, including cancer, inflammation, arthritis, neurodegenerative diseases, cardiovascular diseases, and Fungal diseases, etc.